Ekso Bionics Holdings Inc (NASDAQ:EKSO) reported the release of the EksoGT™ exoskeleton’s FES interface capability via an association with HASOMED. Previously applied for research, HASOMED’s RehaStim2 FES addition with EksoGT exoskeleton is CE Marked and is now offered for routine clinical application in Europe.
Thomas Looby, the CEO and President of Ekso, reported that they strategically work to enhance patient outcome by continually transforming rehabilitation with their exoskeleton technology. The integration of the EksoGT and its advantages, with the RehaStim2 FES know-how, offers clinicians with the latest developments in care, which eventually enhances patient quality of life and clinical outcomes. The synergies between these two know-how mark a vital step in their ability to provide an even more versatile equipment that allows clinicians to offer rehabilitation to an extensive range of patients across varied disease states, including stroke and spinal cord injuries.
FES marks as a technique that utilizes low energy electrical pulses to falsely generate body movements in folks who are paralyzed due to damage to the CNS. Clinical practitioners in EMEA can buy RehaStim2 via HASOMED, or as an advancement, with training delivered by Ekso. The combination of FES and exoskeleton technology, give clinicians the synergistic advantages of earlier muscle stimulation and mobility to offer rehabilitation to a wider spectrum of patients, moving from almost independent to pre-ambulatory.
Matthias Weber, the Owner and CEO of HASOMED, reported that their RehaStim2 FES device transmits electrical impulses to the muscles, resulting in intended movement of extremities in spite of paralysis. Now, through their extended association with Ekso, European rehabilitation experts will have the prospect to offer advanced combination treatment to their patients. The introductory European customer deployment for the EksoGT exoskeleton together with RehaStim2 FES equipment is planned for next month, and is currently offered for investigational research application in the United States.